TRIM32 and metabolic syndrome: Based on these findings, we propose that the TRIM32-INSR to be a potential site for pharmacological interventions as an effective therapy in mitigating obesity-induced hepatic insulin resistance, associated fatty liver disease, and dyslipidemia.